Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus.

{"article_title":"Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus.","author":"\"Chawla, Rajeev , Mukherjee, Jagat Jyoti , Chawla, Manoj , Kanungo, Alok , Shunmugavelu, Meenakshi Sundaram , Das, Ashok Kumar\"","journal_title":"Medical sciences (Basel, Switzerland)","issn":"2076-3271 ; Electronic","isbn":"","publication_date":"20210528","volume":"9","issue":"2","first_page":"","page_count":"","accession_number":"34071359","doi":"10.3390\/medsci9020038","publisher":"MDPI AG","doctype":"Journal Article; Review","subjects":"Diabetes ","interest_area":["Endocrinology"," Internal\/Family Medicine"],"abstract":"Evidence suggests a major contribution of postprandial glucose (PPG) excursions to the increased risk of micro- and macro-vascular complications in individuals with type 2 diabetes mellitus (T2DM). Administration of bolus insulin remains a very effective therapeutic option for PPG control. The aim of this expert group recommendation document was to provide practical and easy-to-execute guidelines for physicians on the appropriate use of bolus insulin in the management of T2DM. A panel of key opinion leaders from India reviewed and discussed the available clinical evidence and guideline recommendations on the following topics: (1) optimum control of PPG; (2) choice of bolus insulin; and (3) special situations and practical considerations. The expert panel critically analyzed the current literature and clinical practice guidelines and factored their rich clinical experience to develop a set of nine expert group recommendations for the effective use of bolus insulin. These recommendations will not only result in a more evidence-based application of bolus insulin in the clinical setting but also trigger further research and provide a valuable base for the development of future guidelines on the use of bolus insulin in the management of individuals with T2DM.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34071359&authtype=shib&custid=ns346513","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Chawla R, Mukherjee JJ, Chawla M, Kanungo A, Shunmugavelu MS, Das AK","Journal_Info":"Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629322 Publication Model: Electronic Cited Medium: Internet ISSN: 2076-3271 (Electronic) Linking ISSN: 20763271 NLM ISO Abbreviation: Med Sci (Basel)","Publication_Type":"Journal Article; Review","Published_Date":"2021-05-28","Source":"Medical sciences (Basel, Switzerland) [Med Sci (Basel)] 2021 May 28; Vol. 9 (2). Date of Electronic Publication: 2021 May 28.","Languages":"English","Electronic_ISSN":"2076-3271","MeSH_Terms":"Diabetes Mellitus, Type 2*\/drug therapy , Insulin*, Humans ; Hypoglycemic Agents ; Insulin, Regular, Human ; Postprandial Period","Subjects":"Humans, Hypoglycemic Agents, Insulin, Regular, Human, Postprandial Period, Diabetes Mellitus, Type 2 drug therapy, Insulin","Title_Abbreviations":"Medical sciences (Basel, Switzerland)","Volume":"9"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"34071359","RelevancyScore":"854","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"854.051147460938"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=34071359&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=34071359&authtype=shib&custid=ns346513&group=main&profile=eds"}